Shares of Regulus Therapeutics Inc. (RGLS) touched a 52-week high of $3.73 during intraday trading yesterday, reflecting continued investor confidence in the company's long-term prospects, particularly its plan to advance its lead drug candidate into a pivotal program later this year.
The lead drug candidate in focus is Farabursen, a novel, next-generation oligonucleotide for the treatment of autosomal dominant polycystic kidney disease, which is a rare genetic disease.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.